Scalper1 News
Big biotech Amgen (AMGN) was up in early trading Wednesday after it announced a neurology partnership with Novartis (NVS) as well as positive data on its osteoporosis drug candidate late Tuesday. Amgen and Novartis agreed to combine their research programs in Alzheimer’s disease, both of which involve drugs in the BACE (beta-site APP-cleaving enzyme-1) inhibitor class. BACE inhibitors, like the more advanced Alzheimer’s disease candidates from Scalper1 News
Scalper1 News